Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05381909 · ClinicalTrials.gov registry record · Phase 1
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
A Phase 1 study, sponsored by BeiGene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 157
- Enrollment target
NCT05381909 is a Phase 1 study that was terminated before completion, run by BeiGene. The registered enrollment target is 157 participants.
The verdict
NCT05381909, a Phase 1 study, was terminated before completion, sponsored by BeiGene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 157 participants
- Enrollment target
Study Summary
This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG BGB-24714
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2022-07-06 |
| Est. Completion | 2025-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05381909
The ClinicalTrials.gov registry entry for NCT05381909 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT05381909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05381909 about?
NCT05381909 is a clinical study titled "A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors". This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered...
What is the current status of trial NCT05381909?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 157 participants. The study started on 2022-07-06. Estimated completion is 2025-07-25.
What interventions are being tested in trial NCT05381909?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), BGB-24714 (DRUG).
Who is sponsoring clinical trial NCT05381909?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.